US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

Detalles Bibliográficos
Autores principales: Echols, Roger M, Nagata, Tsutae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366820/
https://www.ncbi.nlm.nih.gov/pubmed/34398951
http://dx.doi.org/10.1093/cid/ciab010
_version_ 1783738956956827648
author Echols, Roger M
Nagata, Tsutae
author_facet Echols, Roger M
Nagata, Tsutae
author_sort Echols, Roger M
collection PubMed
description
format Online
Article
Text
id pubmed-8366820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83668202021-08-17 US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication Echols, Roger M Nagata, Tsutae Clin Infect Dis Correspondence Oxford University Press 2021-01-07 /pmc/articles/PMC8366820/ /pubmed/34398951 http://dx.doi.org/10.1093/cid/ciab010 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Correspondence
Echols, Roger M
Nagata, Tsutae
US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title_full US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title_fullStr US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title_full_unstemmed US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title_short US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
title_sort us fda’s assessment of the benefit-risk of cefiderocol for its initial complicated urinary tract infection indication
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366820/
https://www.ncbi.nlm.nih.gov/pubmed/34398951
http://dx.doi.org/10.1093/cid/ciab010
work_keys_str_mv AT echolsrogerm usfdasassessmentofthebenefitriskofcefiderocolforitsinitialcomplicatedurinarytractinfectionindication
AT nagatatsutae usfdasassessmentofthebenefitriskofcefiderocolforitsinitialcomplicatedurinarytractinfectionindication

Ejemplares similares